This study includes up to a 3-week Screening Period, followed by a 52-week treatment period. Patients with CIC meeting the entry criteria will receive linaclotide 145-ug capsules, orally, once daily and patients with IBS-C meeting the entry criteria will receive linaclotide 290-ug capsules, orally, once daily.